BLOG

What Does Autologous Mean in NK Cell Therapy? Questions to Ask in Osaka

Published 2026.10.20 7 min read

Hello, I am Dr. Hidenori Shimada of Grand Green Osaka Umekita Clinic in Osaka, Japan.

If you are researching cancer immune cell therapy, you will quickly meet the word “autologous.” It simply means that the cells used in treatment come from your own body. At Grand Green Osaka Umekita Clinic in Osaka, NK (natural killer) cell therapy follows this approach: cells are collected from your blood, activated and expanded outside the body, and returned by intravenous infusion. This article explains what autologous means in practice, what it does and does not imply, and which questions are worth bringing to a consultation.

The short answer: your own cells, not a donor’s

In an autologous therapy, the person who gives the cells is the same person who receives them. This is different from allogeneic therapy, where cells come from another individual, such as a donor. Because the cells are matched to you by definition, the concern about rejection is generally considered lower than with donor-derived cells.

That said, “your own cells” is not a guarantee of an outcome or of safety. It describes where the cells come from, not how well the treatment will work for a particular person. A doctor still needs to assess your situation before any decision is made.

Why NK cells are a natural fit for this approach

NK cells are a type of innate immune cell. They circulate in the blood and can recognize and attack abnormal cells, including cancer cells and virus-infected cells, without waiting for instructions from other immune cells. Researchers describe part of this role as immune surveillance, the ongoing process by which the immune system finds and removes abnormal cells.

NK cell activity is known to decline with age, stress, and the effects of cancer itself. The idea behind NK cell therapy is to take NK cells from a standard blood draw, activate and expand them at a specialized facility, and return a larger number of more active cells to the body. Published studies of NK cell infusions have explored their safety and biological activity, but results vary by cancer type, cell preparation method, and patient condition, so findings from one study should not be generalized to every patient.

What using your own cells may and may not mean

There are several practical points that patients often find helpful to separate clearly.

The risk of immune rejection is generally considered low, because the cells are your own.
Serious side effects have rarely been reported with this type of therapy, but temporary fever or fatigue may occur.
The treatment itself typically involves only a standard blood draw and an intravenous infusion, and usually does not require hospitalization.
Using your own cells does not mean the treatment is risk-free, and it does not mean it will work for everyone.
Using your own cells does not replace standard cancer treatment such as surgery, chemotherapy, or radiation therapy.

The therapy is designed to be considered alongside, not instead of, the treatment your oncologist recommends. If you are currently receiving standard care, it is reasonable to ask both your treating doctor and the clinic how the two might be coordinated.

The quality of your cells still matters

One consequence of using your own cells is that the starting material reflects your current health. A person who has recently had intensive treatment, or whose immune function is low, may yield cells that behave differently from those of another patient. Expansion and activation of cells outside the body also depend on laboratory quality control, so the processing facility is an important part of the overall picture.

In Japan, regenerative medicine of this kind is provided under the Act on the Safety of Regenerative Medicine, with a provision plan submitted to and accepted by the authorities and cells processed at a licensed facility. It is reasonable to ask the clinic to explain how its plan is set up, how the cells are handled, and what happens if a batch does not meet quality standards.

Questions to bring to your consultation

Because NK cell therapy is a self-pay (non-insured) treatment in Japan, the details of eligibility, cost, number of infusions, risks, and side effects should be confirmed directly with a doctor. Questions that many international patients find useful include the following.

Based on my diagnosis and current treatment, is autologous NK cell therapy something you would consider for me, and what are the reasons for or against?
What blood tests or other checks are needed before cells are collected?
How are my cells processed, and how is quality checked before they are returned?
What temporary reactions, such as fever or fatigue, might I experience, and how are they managed?
How would this fit with my surgery, chemotherapy, or radiation schedule, and can you share information with my doctor at home?
What is the total cost, how many infusions are planned, and over what period?
What are the limits of this therapy, and what results should I not expect?

Bringing recent medical records, imaging reports, and a list of current medications, ideally with an English or Japanese summary from your home doctor, can make the first consultation more productive.

Planning from abroad and next steps

Grand Green Osaka Umekita Clinic is located in the Umeda area of Osaka and offers information pages for international patients, so you can review the treatment flow, fees, and frequently asked questions in advance in a language you are comfortable with. A first consultation is the place to ask whether autologous NK cell therapy suits your circumstances, and it is fine to decide not to proceed after hearing the explanation.

To summarize, autologous means the cells come from you, which is why rejection is generally less of a concern. It does not remove uncertainty about effectiveness, and it does not replace standard cancer care. Take your questions, your records, and your oncologist’s input into a consultation, and let a doctor’s individual assessment guide the decision. Please review the NK cell therapy page for details on the flow, fees, risks, and side effects before you decide.

Autologous NK Cell Therapy

Your own NK cellsCells come from your blood
Quality mattersProcessed at a licensed facility
Alongside standard careNot a replacement
Ask your doctorFees, risks and eligibility

This figure is a conceptual summary of the article content

Learn more about NK Cell Therapy

References

Supervising Physician

Director, Medical Corporation Shimada Clinic
Head of Clinical Practice, Grand Green Osaka Umekita Clinic

Hidenori Shimada

Graduated from the University of Tokushima Faculty of Medicine in 2005. After his initial residency, he obtained U.S. medical certification (ECFMG) and trained as a sub-intern in general surgery at the University of Washington. After completing the doctoral program at Kyoto University Graduate School of Medicine and working as a researcher at the Center for iPS Cell Research and Application (CiRA), Kyoto University, he founded Shimada Clinic in 2013. At Grand Green Osaka Umekita Clinic (https://umekitaclinic.org), he is engaged in a wide range of care, from internal medicine and pediatrics to cell therapy and aesthetic medicine.

* The physician supervision of this article covers its academic content only and does not constitute a recommendation of any specific treatment or product.

Back to article list › Back to NK Cell Therapy ›